Earnings Forecast Research on TherapeuticsMD, Inc. (TXMD)

TherapeuticsMD, Inc. has received $-0.12 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 4 Financial Advisor in the Stock Trading Firms. Among 4 Analysts, Bottom line EPS Estimate for the current quarter is $-0.14 while the top line estimate is $-0.11 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -22.5%.

TherapeuticsMD, Inc. results fell short with a surprise EPS of -18.18% or $-0.02. The Actual EPS was $-0.13 compared to the Estimated EPS of $-0.11 during its most recent quarterly earnings.

In the last quarter, TherapeuticsMD, Inc. reported Annual Earnings of $-0.13. Based on the filings, last years Annual Earnings was, $-0.49. In the last Quarter, TXMD reported a surprise Earnings per Share of -18.18% . The consensus estimate for current quarter is $-0.12 and for the current fiscal year, the estimate is $-0.46. For the Next fiscal year, the estimate is $-0.38 based on the consensus.

TherapeuticsMD, Inc. (NYSEMKT:TXMD) : On Tuesday heightened volatility was witnessed in TherapeuticsMD, Inc. (NYSEMKT:TXMD) which led to swings in the share price. The stock opened for trading at $5.61 and hit $5.9 on the upside , eventually ending the session at $5.81, with a gain of 2.83% or 0.16 points. The heightened volatility saw the trading volume jump to 2,055,923 shares. The 52-week high of the share price is $9.29 and the company has a market cap of $1,142 million. The 52-week low of the share price is at $4.39 .

TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida.


Share this post

Leave a Reply